|Title:||The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.||Authors:||Lee, Chee
Davies, Lucy Claire
Gralla, Richard J.
Yang, James Chih-Hsin
|Issue Date:||2015||Journal Volume:||33||Journal Issue:||15||Start page/Pages:||-||Source:||J. Clin. Oncol.||URI:||http://ntur.lib.ntu.edu.tw//handle/246246/280131|
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.